Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Jazz Pharmaceuticals plc Director's Dealing 2020

Mar 10, 2020

30751_dirs_2020-03-10_1a157afb-eae7-4515-bd89-99711658be3d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2020-03-06

Reporting Person: Carr Patricia (VP, Finance & PAO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-03-06 Ordinary Shares S 232 $119.1732 Disposed 7668 Direct
2020-03-09 Ordinary Shares S 568 $111.4481 Disposed 7100 Direct

Footnotes

F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

F2: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $111.4401 to $111.4550. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.